Three amino acids, with copper in the picture
GHK stands for glycine, histidine and lysine. Bound to copper, the tripeptide is called GHK-Cu. It occurs naturally in biological fluids and has been studied in repair and skin biology since the work associated with Loren Pickart.
Copper supports several enzymes involved in connective tissue and antioxidant processes. That role does not mean that a copper-peptide preparation reproduces every effect of those enzymes, nor that age-related changes establish a need for supplementation.
Gene expression is an observation, not age reversal
Changes in gene expression are sometimes described as a youthful reset, but that phrase overstates what the measurement establishes. Gene-expression work measures changes in how genes are read under defined experimental conditions. It does not measure years of human life restored.
Collagen production, matrix metalloproteinases and their inhibitors are part of the research story. These enzymes help remodel the extracellular matrix, the material around cells. Work on repair-cell behaviour and mitochondrial processes is also mechanistic, rather than proof of whole-body rejuvenation.
What is being investigated
| Theme | What it concerns | Limit |
|---|---|---|
| Theme: Skin and scars | What it concerns: Collagen, elastin, wound models and tissue organisation | Limit: Cosmetic appearance and healing of a disease are different outcomes. |
| Theme: Photoageing and oxidative stress | What it concerns: Responses to ultraviolet damage and antioxidant pathways | Limit: This is not evidence of reliable sun protection or systemic detoxification. |
| Theme: Hair follicles | What it concerns: Follicle models, growth-phase biology and local inflammation | Limit: Model findings do not establish reversal of androgenic hair loss. |
| Theme: Bone, vessels and nerves | What it concerns: Connective tissue, vascular signals and neural protection | Limit: These exploratory themes cannot be grouped into a proven systemic treatment. |
| Theme: Inflammation | What it concerns: Cytokines such as TNF-alpha and interleukins, which carry immune signals | Limit: A change in a marker does not by itself show clinical benefit. |
Topical and injectable are separate contexts
Copper Tripeptide-1 is the ingredient name used in cosmetics. Cosmetic regulation does not mean FDA drug approval. Formulation, penetration and the outcome measured all matter when interpreting topical research.
Injectable GHK-Cu is a different regulatory and safety question. Topical observations cannot establish injection schedules, concentrations, microneedling routines or storage windows.
The regulatory distinction
FDA’s page current as of April 22, 2026 lists GHK-Cu for injectable routes of administration as nominated but withdrawn. This withdrawal does not approve injectable GHK-Cu for compounding. The listed safety concerns remain relevant to that route.
Quality is more than a purity percentage
Material identity, copper complexation, degradation and contamination are separate analytical questions. A certificate for one sample does not prove that a formulation reaches its intended tissue, remains stable in a new mixture or produces a clinical effect.
Proposed combinations with BPC-157 and other repair peptides need their own evidence. The same is true for nanoparticle delivery, transdermal systems, personalised gene-expression tracking and possible neurological or bone applications. They remain research directions, rather than a ready-made longevity programme.
What would strengthen the case
Defined formulations, appropriate comparison groups, independent replication and meaningful human outcomes matter more than a broad list of plausible pathways. A gene-expression result, a cosmetic observation and a systemic health claim belong on separate lines of the almanac.